scholarly journals Efficacy and Safety of Bone Marrow Cell Transplantation for Chronic Ischemic Heart Disease: A Meta-Analysis

2014 ◽  
Vol 20 ◽  
pp. 1768-1777 ◽  
Author(s):  
Huozhen Hu
Keyword(s):  
Bone Marrow ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Cell Transplantation ◽  
Bone Marrow Cell ◽  
Marrow Cell ◽  
Meta Analysis ◽  
Ischemic Heart ◽  
Efficacy And Safety ◽  
Chronic Ischemic Heart Disease

Electrophysiological and arrhythmogenic effects of intramyocardial bone marrow cell injection in patients with chronic ischemic heart disease

Heart Rhythm ◽  
2007 ◽  
Vol 4 (3) ◽  
pp. 257-265 ◽  
Author(s):  
Saskia L.M.A. Beeres ◽  
Katja Zeppenfeld ◽  
Jeroen J. Bax ◽  
Petra Dibbets-Schneider ◽  
Marcel P.M. Stokkel ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Bone Marrow Cell ◽  
Marrow Cell ◽  
Ischemic Heart ◽  
Chronic Ischemic Heart Disease ◽  
Cell Injection ◽  
Arrhythmogenic Effects

Bone Marrow Cell Therapy for Ischemic Heart Disease

2015 ◽  
Vol 117 (6) ◽  
pp. 490-493 ◽  
Author(s):  
Giulio Pompilio ◽  
Patrizia Nigro ◽  
Beatrice Bassetti ◽  
Maurizio C. Capogrossi
Keyword(s):  
Bone Marrow ◽  
Heart Disease ◽  
Cell Therapy ◽  
Ischemic Heart Disease ◽  
Bone Marrow Cell ◽  
Marrow Cell ◽  
Ischemic Heart ◽  
Bone Marrow Cell Therapy

Abstract 14451: Bone Marrow Cell Therapy Improves Cardiac Function, Survival, and Clinical Outcomes in Patients With Chronic Ischemic Heart Disease

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Jane Ha ◽  
Muhammad R Afzal ◽  
Anweshan Samanta ◽  
Ewa Zuba-Surma ◽  
Ji Yoo ◽  
...  
Keyword(s):  
Heart Failure ◽  
Bone Marrow ◽  
Heart Disease ◽  
Cardiac Function ◽  
Ischemic Heart Disease ◽  
Clinical Outcomes ◽  
Ventricular Arrhythmias ◽  
Marrow Cell ◽  
Meta Analysis ◽  
Chronic Ischemic Heart Disease

Introduction: The effects of bone marrow cell (BMC) therapy in patients with chronic ischemic heart disease (CIHD) remain controversial. Hypothesis: We hypothesized that injection of BMCs in patients with CIHD would improve left ventricular (LV) structure and function. We also hypothesized that BMC therapy would improve clinical outcomes in CIHD patients. Methods: We performed a systemic review and meta-analysis of pooled data from published randomized controlled trials (RCTs) that evaluated the efficacy of BMC administration in patients with CIHD. The effects of BMC injection on LV ejection fraction (LVEF), LV end-systolic volume (LVESV), LV end-diastolic volume (LVEDV), infarct size, and patient outcomes were analyzed using random-effects meta-analysis. Results: The literature search yielded 30 RCTs enrolling 1,548 patients. Transplantation of BMCs resulted in an improvement in LVEF in cell-treated patients compared with controls (2.89%; 95% confidence interval (CI): 1.80 to 3.97; P <0.001). There was a trend toward reduced LVESV (-4.96 ml; 95% CI: -11.64 to 1.71 ml; P = 0.14) and LVEDV (-5.95 ml; 95% CI: -12.09 to 0.18 ml; P =0.06). The improvement in LVEDV was more pronounced (-7.42 ml; 95% CI: -13.68 to -1.17ml; P =0.02) in patients with baseline LVEF <40%, indicating improved LV remodeling. BMC injection was also associated with marked reduction in the risk of all-cause mortality, rehospitalization due to heart failure, and ventricular arrhythmias in CIHD patients. Conclusions: BMC injection improves cardiac function and remodeling in patients with CIHD. These benefits are more pronounced in patients with LVEF <40% at baseline. Perhaps more importantly, BMC therapy also improves clinical outcomes that are critically important for this patient population with LV dysfunction, including survival, rehospitalization due to heart failure, and ventricular arrhythmias.

Sign in / Sign up

Export Citation Format

Share Document